| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2004.11.010 |
| P698 | PubMed publication ID | 15734046 |
| P2093 | author name string | Clements JD | |
| Freytag LC | |||
| P2860 | cites work | CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma | Q24568172 |
| Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs | Q24644853 | ||
| The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice | Q74586019 | ||
| Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines | Q74733696 | ||
| Mutation of a buried residue causes loss of activity but no conformational change in the heat-labile enterotoxin of Escherichia coli | Q27730290 | ||
| Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria | Q29619620 | ||
| Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection | Q30328172 | ||
| Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen | Q33591055 | ||
| Adjuvant activity of a nontoxic mutant of Escherichia coli heat-labile enterotoxin on systemic and mucosal immune responses elicited against a heterologous antigen carried by a live Salmonella enterica serovar Typhimurium vaccine strain | Q33599389 | ||
| Intranasal administration of 2/6-rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs | Q33604018 | ||
| Potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin: receptor binding is essential and induces differential modulation of lymphocyte subsets | Q33611559 | ||
| Antibody-dependent and -independent protection following intranasal immunization of mice with rotavirus particles | Q33649920 | ||
| Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 or VP6 protein. | Q33649962 | ||
| Functional mapping of protective domains and epitopes in the rotavirus VP6 protein | Q33812420 | ||
| Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. | Q33840918 | ||
| Collaboration of epithelial cells with organized mucosal lymphoid tissues. | Q33955758 | ||
| Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization | Q33999182 | ||
| Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants | Q34001658 | ||
| Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. | Q34002470 | ||
| Differential biological and adjuvant activities of cholera toxin and Escherichia coli heat-labile enterotoxin hybrids | Q34006327 | ||
| Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection | Q34007563 | ||
| Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis | Q34122078 | ||
| Mechanisms of monophosphoryl lipid A augmentation of host responses to recombinant HagB from Porphyromonas gingivalis | Q34126807 | ||
| Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge | Q34130795 | ||
| Genetically manipulated bacterial toxin as a new generation mucosal adjuvant | Q34184890 | ||
| Immunomodulation using bacterial enterotoxins | Q34184898 | ||
| Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. | Q34189195 | ||
| Vaccination against Helicobacter pylori in non-human primate models and humans | Q34222750 | ||
| Targeting of cholera toxin and Escherichia coli heat labile toxin in polarized epithelia: role of COOH-terminal KDEL | Q34289590 | ||
| CpG motifs in bacterial DNA trigger direct B-cell activation | Q34307394 | ||
| Activation of the immune system by bacterial CpG-DNA. | Q34579763 | ||
| Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants | Q34639828 | ||
| Role of Innate Immune Factors in the Adjuvant Activity of Monophosphoryl Lipid A | Q34933694 | ||
| Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant | Q35476128 | ||
| Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor beta1 and beta2 chain expression | Q36367736 | ||
| Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection | Q36369774 | ||
| Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice | Q37584470 | ||
| Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis. | Q38303976 | ||
| Induction of systemic immune responses to measles virus synthetic peptides administered intranasally | Q39055934 | ||
| The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunization with a synthetic peptide | Q39340710 | ||
| Inhibition of T-cell response by Escherichia coli heat-labile enterotoxin-treated epithelial cells. | Q39517330 | ||
| Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants | Q39538202 | ||
| Protective antiviral immune responses to pseudorabies virus induced by DNA vaccination using dimethyldioctadecylammonium bromide as an adjuvant | Q39684976 | ||
| Epithelial cells as sensors for microbial infection | Q39786521 | ||
| Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity | Q39821844 | ||
| Enhancing effect of cholera toxin on interleukin-6 secretion by IEC-6 intestinal epithelial cells: mode of action and augmenting effect of inflammatory cytokines. | Q40269379 | ||
| Contribution of the ADP-ribosylating and receptor-binding properties of cholera-like enterotoxins in modulating cytokine secretion by human intestinal epithelial cells | Q40746380 | ||
| Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity | Q40843925 | ||
| The role of Th1 and Th2 cells for mucosal IgA responses. | Q40976411 | ||
| Cholera toxin enhances alloantigen presentation by cultured intestinal epithelial cells | Q41561732 | ||
| Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues | Q41850548 | ||
| Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity | Q41855397 | ||
| Cholera toxin is exported from microsomes by the Sec61p complex | Q41861735 | ||
| The adjuvant action of cholera toxin is associated with an increased intestinal permeability for luminal antigens | Q41915577 | ||
| Phospholipase A2 activating protein and idiopathic inflammatory bowel disease | Q42000831 | ||
| Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL. | Q42833971 | ||
| Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis | Q43702777 | ||
| Targeting polymerised liposome vaccine carriers to intestinal M cells | Q43745138 | ||
| Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. | Q43981500 | ||
| Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells | Q44191604 | ||
| Induction of intestinal IgA and IgG antibodies preventing adhesion of verotoxin-producing Escherichia coli to Caco-2 cells by oral immunization with liposomes | Q44311804 | ||
| Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine | Q45018054 | ||
| Active immunity and T-cell populations in pigs intraperitoneally inoculated with baculovirus-expressed transmissible gastroenteritis virus structural proteins | Q45746948 | ||
| Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses | Q45754936 | ||
| Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli | Q47773545 | ||
| Effects of intranasal administration of cholera toxin (or Escherichia coli heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain | Q49046324 | ||
| LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp. | Q50131343 | ||
| Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. | Q51187990 | ||
| Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection. | Q51546562 | ||
| Common features of the NAD-binding and catalytic site of ADP-ribosylating toxins. | Q52540113 | ||
| Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. | Q53949766 | ||
| Role of B7 costimulatory molecules in the adjuvant activity of the heat-labile enterotoxin of Escherichia coli. | Q54540479 | ||
| Modulation of B-cell activation by the B subunit of Escherichia coli enterotoxin: receptor interaction up-regulates MHC class II, B7, CD40, CD25 and ICAM-1. | Q54560579 | ||
| Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. | Q54593091 | ||
| Protein Disulfide Isomerase Acts as a Redox-Dependent Chaperone to Unfold Cholera Toxin | Q57180002 | ||
| The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity | Q67542118 | ||
| Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin | Q71643281 | ||
| Helper Th1 and Th2 cell responses following mucosal or systemic immunization with cholera toxin | Q72845022 | ||
| Cholera toxin adjuvant greatly promotes antigen priming of T cells | Q72921086 | ||
| The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT) | Q73028927 | ||
| Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae | Q73188461 | ||
| Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G) | Q73502942 | ||
| Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration | Q73594822 | ||
| ARF binds the C-terminal region of the Escherichia coli heat-labile toxin (LTA1) and competes for the binding of LTA2 | Q73732822 | ||
| Characterization of the antibody response to pneumococcal glycoconjugates and the effect of heat-labile enterotoxin on IGg subclasses after intranasal immunization | Q73799949 | ||
| Enterotoxin adjuvants have direct effects on T cells and antigen-presenting cells that result in either interleukin-4-dependent or -independent immune responses | Q73959658 | ||
| Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants | Q73980726 | ||
| Immunogenicity of anti-Haemophilus influenzae type b CRM197 conjugate following mucosal vaccination with oligodeoxynucleotide containing immunostimulatory sequences as adjuvant | Q74092627 | ||
| Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming | Q74165263 | ||
| Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine | Q74484589 | ||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1804-1813 | |
| P577 | publication date | 2005-03-01 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Mucosal adjuvants. | |
| P478 | volume | 23 |
| Q90621575 | A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization |
| Q33901777 | A Recombinant 47-kDa Outer Membrane Protein Induces an Immune Response against Orientia tsutsugamushi Strain Boryong |
| Q36969236 | A live attenuated Salmonella Enteritidis secreting detoxified heat labile toxin enhances mucosal immunity and confers protection against wild-type challenge in chickens. |
| Q46974867 | A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice |
| Q45083603 | Adjuvant effect of Escherichia coli heat labile enterotoxin B subunit against internal egg contamination in domestic fowl immunised with a live Salmonella enterica serovar Enteritidis vaccine. |
| Q92283566 | Adjuvant effect of enterotoxigenic Escherichia coli (ETEC) double-mutant heat-labile toxin (dmLT) on systemic immunogenicity induced by the CFA/I/II/IV MEFA ETEC vaccine: Dose-related enhancement of antibody responses to seven ETEC adhesins (CFA/I, |
| Q47835607 | Adjuvant requirement for successful immunization with recombinant derivatives of Plasmodium vivax merozoite surface protein-1 delivered via the intranasal route |
| Q38055323 | Adjuvants for allergy vaccines |
| Q33802696 | An oral vaccine based on U-Omp19 induces protection against B. abortus mucosal challenge by inducing an adaptive IL-17 immune response in mice |
| Q38356275 | An overview of tuberculosis plant-derived vaccines |
| Q37191376 | Anthrax edema toxin induces maturation of dendritic cells and enhances chemotaxis towards macrophage inflammatory protein 3beta |
| Q37724863 | Archaeal lipid mucosal vaccine adjuvant and delivery system |
| Q50021411 | Attenuated Salmonella Gallinarum secreting an Escherichia coli heat-labile enterotoxin B subunit protein as an adjuvant for oral vaccination against fowl typhoid |
| Q33909162 | Binding to gangliosides containing N-acetylneuraminic acid is sufficient to mediate the immunomodulatory properties of the nontoxic mucosal adjuvant LT-IIb(T13I) |
| Q90356536 | Biochemical and immunological characterization of an ETEC CFA/I adhesin cholera toxin B subunit chimera |
| Q44205583 | Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant |
| Q41729708 | Characterization of a Salmonella Typhimurium ghost carrying an adjuvant protein as a vaccine candidate for the protection of chickens against virulent challenge |
| Q35066293 | Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. |
| Q34972133 | Characterization of antigen-presenting cells induced by intragastric immunization with recombinant chimeric immunogens constructed from Streptococcus mutans AgI/II and type I or type II heat-labile enterotoxins |
| Q34026162 | Cholera toxin - a foe & a friend. |
| Q86057131 | Cholera toxin adjuvant promotes a balanced Th1/Th2/Th17 response independently of IL-12 and IL-17 by acting on Gsα in CD11b⁺ DCs |
| Q47645568 | Cholera toxin enhances IL-17A production in both CD4+ and CD8+ cells via a cAMP/PKA-mediated IL-17A promoter activation. |
| Q37954306 | Cholera-like enterotoxins and Regulatory T cells |
| Q47164620 | Clostridium difficile flagellin FliC: Evaluation as adjuvant and use in a mucosal vaccine against Clostridium difficile. |
| Q36191001 | Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs |
| Q41740590 | Comparative evaluation of Salmonella Enteritidis ghost vaccines with a commercial vaccine for protection against internal egg contamination with Salmonella |
| Q41732736 | Comparative evaluation of safety and efficacy of a live Salmonella gallinarum vaccine candidate secreting an adjuvant protein with SG9R in chickens. |
| Q35652988 | Comparison of a live attenuated Salmonella Enteritidis vaccine candidate secreting Escherichia coli heat-labile enterotoxin B subunit with a commercial vaccine for efficacy of protection against internal egg contamination by Salmonella in hens. |
| Q52880878 | Construction and preclinical evaluation of mmCT, a novel mutant cholera toxin adjuvant that can be efficiently produced in genetically manipulated Vibrio cholerae. |
| Q34381599 | Construction of a recombinant-attenuated Salmonella Enteritidis strain secreting Escherichia coli heat-labile enterotoxin B subunit protein and its immunogenicity and protection efficacy against salmonellosis in chickens. |
| Q45372811 | Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant |
| Q51049621 | Cross-protection conferred by immunization with an rOmpH-based intranasal fowl cholera vaccine. |
| Q38784950 | Current prospects and future challenges for nasal vaccine delivery. |
| Q28748926 | Defensins as anti-inflammatory compounds and mucosal adjuvants |
| Q37354182 | Delivery systems: a vaccine strategy for overcoming mucosal tolerance? |
| Q30368221 | Development of stable influenza vaccine powder formulations: challenges and possibilities |
| Q36744330 | Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens |
| Q80126897 | Effect of sublingual administration with a native or denatured protein allergen and adjuvant CpG oligodeoxynucleotides or cholera toxin on systemic T(H)2 immune responses and mucosal immunity in mice |
| Q46041570 | Effect of tape stripping and adjuvants on immune response after intradermal DNA electroporation |
| Q34738751 | Enhancement of immune responses by an attenuated Salmonella enterica serovar Typhimurium strain secreting an Escherichia coli heat-labile enterotoxin B subunit protein as an adjuvant for a live Salmonella vaccine candidate |
| Q39218689 | Enterotoxigenic Escherichia coli heat-stable toxin and heat-labile toxin toxoid fusion 3xSTaN12S-dmLT induces neutralizing anti-STa antibodies in subcutaneously immunized mice |
| Q35754880 | Evaluating the A-Subunit of the Heat-Labile Toxin (LT) As an Immunogen and a Protective Antigen Against Enterotoxigenic Escherichia coli (ETEC). |
| Q40846782 | Evaluation of immunogenicity and protective efficacy of adjuvanted Salmonella Typhimurium ghost vaccine against salmonellosis in chickens |
| Q37064556 | Evaluation of protective efficacy induced by virus-like particles containing a Trichinella spiralis excretory-secretory (ES) protein in mice |
| Q46602469 | Evaluation of the adjuvant effect of Salmonella-based Escherichia coli heat-labile toxin B subunits on the efficacy of a live Salmonella-delivered avian pathogenic Escherichia coli vaccine |
| Q46707928 | Evidence for adjuvanticity of anthrax edema toxin |
| Q33650861 | Formulation and characterization of nanoemulsion intranasal adjuvants: effects of surfactant composition on mucoadhesion and immunogenicity |
| Q45412610 | Formulation with CpG ODN enhances antibody responses to an equine influenza virus vaccine |
| Q34568384 | Functional diversity of heat-labile toxins (LT) produced by enterotoxigenic Escherichia coli: differential enzymatic and immunological activities of LT1 (hLT) AND LT4 (pLT) |
| Q54393653 | GITR contributes to the systemic adjuvanticity of the Escherichia coli heat-labile enterotoxin. |
| Q40212185 | Generation of a safe Salmonella Gallinarum vaccine candidate that secretes an adjuvant protein with immunogenicity and protective efficacy against fowl typhoid. |
| Q35833473 | Immunization with a Double-Mutant (R192G/L211A) of the Heat-Labile Enterotoxin of Escherichia coli Offers Partial Protection against Campylobacter jejuni in an Adult Mouse Intestinal Colonization Model |
| Q33738499 | Immunization with the recombinant Cholera toxin B fused to Fimbria 2 protein protects against Bordetella pertussis infection |
| Q46308392 | Immunization without needles |
| Q28972559 | Immunology of Gut Mucosal Vaccines |
| Q33778331 | Immunospecific responses to bacterial elongation factor Tu during Burkholderia infection and immunization |
| Q37238638 | In vivo and in vitro adjuvant activities of the B subunit of Type IIb heat-labile enterotoxin (LT-IIb-B5) from Escherichia coli. |
| Q34717084 | Induction of heterosubtypic immunity to influenza virus by intranasal immunization |
| Q37461092 | Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine |
| Q81157484 | Induction of neutralizing antibodies by a tobacco chloroplast-derived vaccine based on a B cell epitope from canine parvovirus |
| Q42193505 | Influence of Brucella abortus lipopolysaccharide as an adjuvant on the immunogenicity of HPV-16 L1VLP vaccine in mice. |
| Q45107740 | Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection |
| Q47790283 | Intranasal immunization with a mixture of PspA and a Toll-like receptor agonist induces specific antibodies and enhances bacterial clearance in the airways of mice |
| Q28744570 | Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection |
| Q36837156 | Intranasal vaccines for protection against respiratory and systemic bacterial infections. |
| Q34545847 | Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and protects against rotavirus infection in mice |
| Q37316013 | Is intranasal vaccination a feasible solution for tuberculosis? |
| Q43243181 | Kinetic analysis and evaluation of the mechanisms involved in the resolution of experimental nontypeable Haemophilus influenzae-induced otitis media after transcutaneous immunization |
| Q37157157 | Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination |
| Q83936984 | Lactococcus lactis GEM particles displaying pneumococcal antigens induce local and systemic immune responses following intranasal immunization |
| Q37641941 | Mechanisms of Cholera Toxin in the Modulation of TH17 Responses |
| Q34647668 | Mice develop effective but delayed protective immune responses when immunized as neonates either intranasally with nonliving VP6/LT(R192G) or orally with live rhesus rotavirus vaccine candidates |
| Q37459402 | Modulation of protective immunity against herpes simplex virus via mucosal genetic co-transfer of DNA vaccine with beta2-adrenergic agonist |
| Q33935005 | Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax |
| Q36517179 | Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity |
| Q37290114 | Mucosal vaccination against bacterial respiratory infections |
| Q36758075 | Mucosal vaccine adjuvants update |
| Q38727453 | Mucosal vaccine delivery: Current state and a pediatric perspective |
| Q35689341 | Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants. |
| Q35858827 | NKp46+ Innate Lymphoid Cells Dampen Vaginal CD8 T Cell Responses following Local Immunization with a Cholera Toxin-Based Vaccine. |
| Q36826926 | Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae |
| Q43623067 | Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice |
| Q59795793 | Needle-Free Immunization with Chitosan-Based Systems |
| Q47979035 | Neonatal vaccination with Mycobacterium bovis BCG: potential effects as a priming agent shown in a heterologous prime-boost immunization protocol |
| Q36880291 | Nod2-mediated recognition of the microbiota is critical for mucosal adjuvant activity of cholera toxin |
| Q60912609 | Oral co-administration of a bacterial protease inhibitor in the vaccine formulation increases antigen delivery at the intestinal epithelial barrier |
| Q36640081 | Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells |
| Q34707653 | Oral immunization with an attenuated Salmonella Gallinarum mutant as a fowl typhoid vaccine with a live adjuvant strain secreting the B subunit of Escherichia coli heat-labile enterotoxin |
| Q79859166 | Oral tolerance induction by mucosal administration of cholera toxin B-coupled antigen involves T-cell proliferation in vivo and is not affected by depletion of CD25+ T cells |
| Q52648767 | PLGA particulate subunit tuberculosis vaccines promote humoral and Th17 responses but do not enhance control of Mycobacterium tuberculosis infection. |
| Q51495627 | Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors. |
| Q38823962 | Plant-based vaccines against respiratory diseases: current status and future prospects |
| Q36530216 | Postgenomic approaches to cholera vaccine development |
| Q34154378 | Probing local innate immune responses after mucosal immunisation |
| Q34920929 | Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D. |
| Q36755687 | Production of hepatitis B surface antigen in recombinant plant systems: an update |
| Q34490385 | Progress towards an effective syphilis vaccine: the past, present and future |
| Q37207581 | Prospects for use of interleukin-12 as a mucosal adjuvant for vaccination of humans to protect against respiratory pneumococcal infection. |
| Q45374296 | Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein |
| Q30362954 | Protection of mice from H5N1 influenza challenge by prophylactic DNA vaccination using particle mediated epidermal delivery. |
| Q40302309 | Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant. |
| Q35252487 | Protectivity conferred by immunization with intranasal recombinant outer membrane protein H from Pasteurella multocida serovar A:1 in chickens |
| Q37286320 | Quantitative Proteomic Analysis of Escherichia coli Heat-Labile Toxin B Subunit (LTB) with Enterovirus 71 (EV71) Subunit VP1 |
| Q47425162 | Ragweed pollen as an oral vaccine delivery system: Mechanistic insights. |
| Q38068954 | Recent progress towards development of a Shigella vaccine |
| Q36391313 | Recombinant outer membrane protein F-B subunit of LT protein as a prophylactic measure against Pseudomonas aeruginosa burn infection in mice |
| Q45326330 | Recombinant-attenuated Salmonella pullorum strain expressing the hemagglutinin-neuraminidase (HN) protein of Newcastle disease virus (NDV) protects chickens against NDV and Salmonella Pullorum challenge |
| Q45384700 | Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles |
| Q37547763 | Resistance to infection, early and persistent suppression of simian immunodeficiency virus SIVmac251 viremia, and significant reduction of tissue viral burden after mucosal vaccination in female rhesus macaques |
| Q37742184 | Role of secretory immunoglobulin A and secretory component in the protection of mucosal surfaces |
| Q37335500 | Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli |
| Q41637482 | Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study |
| Q34784973 | Safety and immunogenicity of escalating dosages of a single oral administration of peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli and Vibrio cholerae |
| Q33743411 | Salmonella enterica serovar enteritidis ghosts carrying the Escherichia coli heat-labile enterotoxin B subunit are capable of inducing enhanced protective immune responses |
| Q42174414 | Salmonella ghosts expressing enterotoxigenic Escherichia coli k88ab, k88ac, k99, and fasa fimbrial antigens induce robust immune responses in a mouse model |
| Q36744991 | Should a new tuberculosis vaccine be administered intranasally? |
| Q100569000 | Stability studies of the vaccine adjuvant U-Omp19 |
| Q47305690 | Structural Characterization and Physicochemical Stability Profile of a Double Mutant Heat Labile Toxin Protein Based Adjuvant |
| Q33323372 | Sub-nucleocapsid nanoparticles: a nasal vaccine against respiratory syncytial virus |
| Q50041664 | Sublingual vaccination with sonicated Salmonella proteins and mucosal adjuvant induces mucosal and systemic immunity and protects mice from lethal enteritis |
| Q40372154 | Systemic and mucosal pre-administration of recombinant Helicobacter pylori neutrophil-activating protein prevents ovalbumin-induced allergic asthma in mice |
| Q34270342 | The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens |
| Q37628867 | The ABC of clinical and experimental adjuvants--a brief overview |
| Q57945015 | The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT |
| Q26798471 | The Role of Mucosal Associated Invariant T Cells in Antimicrobial Immunity |
| Q34532223 | The adjuvant double mutant Escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigens |
| Q36256348 | The catalytic A1 domains of cholera toxin and heat-labile enterotoxin are potent DNA adjuvants that evoke mixed Th1/Th17 cellular immune responses |
| Q36844715 | The perfect mix: recent progress in adjuvant research |
| Q49105055 | The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection |
| Q37791415 | Topical immunization strategies |
| Q42061615 | Transcutaneous immunization as preventative and therapeutic regimens to protect against experimental otitis media due to nontypeable Haemophilus influenzae |
| Q37130475 | Type I interferons as vaccine adjuvants against infectious diseases and cancer |
| Q37647549 | U-Omp19 from Brucella abortus Is a Useful Adjuvant for Vaccine Formulations against Salmonella Infection in Mice |
| Q35155937 | Unexpected modulation of recall B and T cell responses after immunization with rotavirus-like particles in the presence of LT-R192G. |
| Q27311087 | Unlipidated outer membrane protein Omp16 (U-Omp16) from Brucella spp. as nasal adjuvant induces a Th1 immune response and modulates the Th2 allergic response to cow's milk proteins |
| Q34594874 | Vaccines against enterotoxigenic Escherichia coli |
| Q34369729 | Vaccines against gonorrhea: current status and future challenges. |
| Q39159453 | WH1fungin a surfactin cyclic lipopeptide is a novel oral immunoadjuvant |
Search more.